Deflamin bioactivities : a novel inhibitory protein of MMP-9 from lupinus albus
Today, high-stressed lives paired with an increase in life expectancy lead to a natural increase in chronic diseases, which inexorably boosts medical and pharmaceutical costs worldwide. Despite the substantial advances in the treatment of complex, multigenic and chronic human diseases, their occurrence rate is still increasing significantly in the recent times. Also, many times traditional clinical treatments are not completely effective and have major disadvantages such as high cost and adverse side effects (Kunnumakkara et al., 2016). Hence, the development of cost effective, readily available, non-toxic and highly effective agents for the management of different human diseases are a rapidly increasing and desired area of research.